EGFR mutation up-regulates EGR1 expression through the ERK pathway

Anticancer Research

Volumn 29, Issue 4, 2009, Pages 1111-1118

  Maegawa, Mari ^a,b   Arao, Tokuzo ^a   Yokote, Hideyuki ^a   Matsumoto, Kazuko ^a   Kudo, Kanae ^a   Tanaka, Kaoru ^a   Kaneda, Hiroyasu ^a   Fujita, Yoshihiko ^a   Fumiaki, Ito ^b   Nishio, Kazuto ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SETSUNAN UNIVERSITY   (Japan)

Author keywords

EGFR; EGR1; Microarray; Mutation

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; EARLY GROWTH RESPONSE FACTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE;

ARTICLE; CELL STRAIN HEK293; EMBRYO; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MUTANT; MUTATION; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STIMULATION; WILD TYPE;

CELLS, CULTURED; EARLY GROWTH RESPONSE PROTEIN 1; GENE EXPRESSION PROFILING; HUMANS; IMMUNOBLOTTING; KIDNEY; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 64949151580     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Cowley GP, Smith JA and Gusterson BA: Increased EGF receptors on human squamous carcinoma cell lines. Br J Cancer 53: 223-229, 1986.
2. Gusterson B, Cowley G, Mcllhinney J, Ozanne B, Fisher C and Reeves B: Evidence for increased epidermal growth factor receptors in human sarcomas. Int J Cancer 36: 689-693, 1985.
3. Karamouzis MV, Grandis JR and Argiris A: Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA 298: 70-82, 2007.
4. Rocha-Lima CM, Soares HP, Raez LE and Singal R: EGFR targeting of solid tumors. Cancer Control 14: 295-304, 2007.
5. Mitsudomi T, Kosaka T, Endoh H et al: Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23: 2513- 2520,2005.
6. Paez JG, Janne PA, Lee JC et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004.
7. Pao W, Miller V, Zakowski M et al: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306-13311, 2004.
8. Tokumo M, Toyooka S, Kiura K et al: The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 11: 1167-1173,2005.
9. Amann J, Kalyankrishna S, Massion PP et al: Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 65: 226-235,2005.
10. Arao T, Fukumoto H, Takeda M, Tamura T, Saijo N and Nishio K: Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474. Cancer Res 64: 9101-9104, 2004.
11. Koizumi F, Shimoyama T, Taguchi F, Saijo N and Nishio K: Establishment of a human non-small cell lung cancer cell line resistant to gefitinib. Int J Cancer 116: 36-44, 2005.
12. Sakai K, Arao T, Shimoyama T et al: Dimerization and the signal transduction pathway of a small in-frame deletion in the epidermal growth factor receptor. FASEB J 20: 311-313, 2006.
13. Sakai K, Yokote H, Murakami-Murofushi K, Tamura T, Saijo N and Nishio K: In-frame deletion in the EGF receptor alters kinase inhibition by gefitinib. Biochem J 397: 537-543, 2006.
14. Matsumoto K, Yokote H, Arao T et al: N-Glycan fucosylation of epidermal growth factor receptor modulates receptor activity and sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor. Cancer Sci 99: 1611-1617, 2008.
15. Igarashi T, Izumi H, Uchiumi T et al: Clock and ATF4 transcription system regulates drug resistance in human cancer cell lines. Oncogene 26: 4749-4760, 2007.
16. Lo LW, Cheng JJ, Chiu JJ, Wung BS, Liu YC and Wang DL: Endothelial exposure to hypoxia induces Egr-1 expression involving PKCalpha-mediated Ras/Raf-l/ERKl/2 pathway. J Cell Physiol 188: 304-312, 2001.
17. Adamson ED and Mercola D: Egrl transcription factor: multiple roles in prostate tumor cell growth and survival. Tumour Biol 23: 93-102, 2002.
18. Baron V, Adamson ED, Calogero A, Ragona G and Mercola D: The transcription factor Egrl is a direct regulator of multiple tumor suppressors including TGFbetal, PTEN, p53, and fibronectin. Cancer Gene Ther 13: 115-124, 2006.
19. Adamson E, de Belle I, Mittal S et al: Egrl signaling in prostate cancer. Cancer Biol Ther 2: 617-622, 2003.
20. Lynch TJ, Bell DW, Sordella R et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129- 2139, 2004.
21. Ferraro B, Bepler G, Sharma S, Cantor A and Haura EB: EGR1 predicts PTEN and survival in patients with non-small-cell lung cancer. J Clin Oncol 23: 1921-1926, 2005.
22. Silverman ES and Collins T: Pathways of Egr-1-mediated gene transcription in vascular biology. Am J Pathol 154: 665-670, 1999.